NGGT Inc.

From the team at NGGT to all of you – Happy Holidays!

Haven’t yet had the chance to visit us on the web? Make sure to go to nggtbio.com to learn more about NGGT, find the latest media coverage and news, and explore our innovative #genetherapy technology, product pipeline and advanced manufacturing capabilities.

NGGT announced results from an investigator-initiated trial with its #genetherapy NGGT002 in #phenylketonuria, which led to a lasting reduction in patient plasma phenylalanine levels. Read the news release here: prn.to/3Ckh53s

Recruiting for our phase I/II clinical trial to evaluate safety and efficacy of our #genetherapy asset NGGT-002 in classic #phenylketonuria (PKU) patients has begun! Learn more about the study and eligibility criteria here: bit.ly/3XITwIy

Our phase I/II clinical trial to evaluate safety and efficacy of our #genetherapy asset NGGT-002 in classic #phenylketonuria (PKU) patients will begin recruiting in September! Learn more about the study and eligibility criteria here: clinicaltrials.gov/study/NCT06332…

What a tremendous experience at the @NPKUA_Info 2024 conference! It was great to interact with the #PKU community and to present new data on the safety and efficacy of our #genetherapy asset NGGT002 in #phenylketonuria patients.

Our Co-Founder and COO Guang Qu joined @KarenJagoda on the Empowered Patient podcast to discuss our gene therapy technology and trials for Bietti’s Crystalline Dystrophy and #phenylketonuria. Listen here: bit.ly/4bk4Xva